Vecuronium Pediatric Dose — Neuromuscular Blockade
Vecuronium is a non-depolarizing neuromuscular blocking agent (NMBA) that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle relaxation. It is used in pediatric patients to facilitate endotracheal intubation, maintain paralysis during mechanical ventilation, and support procedural immobility in the ICU setting.
Pediatric Dosing
- Dose: 0.1–0.2 mg/kg IV per dose
- Duration of effect: approximately 20–40 minutes per dose
Higher doses within the range (0.2 mg/kg) are typically used when more rapid onset or a longer initial duration of blockade is desired, such as during rapid sequence intubation (RSI). Consult institutional protocol for repeat dosing intervals and total cumulative dose guidance.
Worked example: For a 20 kg child: 20 × 0.1 mg/kg = 2 mg (low end) to 20 × 0.2 mg/kg = 4 mg (high end) IV per dose.
Indications and Clinical Context
Vecuronium is indicated in pediatric patients requiring neuromuscular blockade for endotracheal intubation, facilitation of mechanical ventilation, or procedures requiring complete immobility. As a non-depolarizing NMBA, it is preferred when succinylcholine is contraindicated (e.g., hyperkalemia risk, known or suspected myopathy, denervation injury). It is used within RSI protocols and ICU management in conjunction with adequate sedation and analgesia, consistent with PALS and critical care guidelines.
Neuromuscular blocking agents must always be paired with appropriate sedation and analgesia, as NMBAs provide no anesthetic, analgesic, or amnestic properties. Clinical reassessment of the need for ongoing blockade is essential.
Administration and Monitoring
Vecuronium is administered as an IV bolus. Ensure secure intravenous access prior to administration; intraosseous (IO) access may be used in emergencies per institutional protocol. Onset of action is approximately 2–3 minutes, with clinical paralysis lasting 20–40 minutes per dose.
- Administer only after confirming adequate sedation and analgesia are in place or being concurrently given.
- Monitor for adequacy of neuromuscular blockade and titrate per train-of-four (TOF) assessment in sustained paralysis scenarios.
- Common adverse effects include prolonged neuromuscular blockade (particularly in renal or hepatic impairment), tachycardia, and, rarely, hypersensitivity reactions.
- Vecuronium is reversible with neostigmine plus an anticholinergic agent (e.g., atropine or glycopyrrolate) once spontaneous recovery begins.
- Consult institutional protocol for maximum single dose and repeat dosing intervals.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.